Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Summary
The study is being conducted to evaluate the safety and tolerability of SHR-4595 for injection in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical studies (RP2D) of SHR-4595.
Official title: An Open-label, Multicenter Phase I Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
208
Start Date
2026-09
Completion Date
2030-12
Last Updated
2026-09-21
Healthy Volunteers
No
Conditions
Interventions
SHR-4595 for Injection
SHR-4595 for injection, in different doses.
Locations (2)
Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute)
Shenyang, Liaoning, China
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China